{"id":122277,"date":"2021-07-19T20:30:00","date_gmt":"2021-07-19T20:30:00","guid":{"rendered":"https:\/\/icrowdnewswire.com\/?p=2892887"},"modified":"2021-07-19T20:30:00","modified_gmt":"2021-07-19T20:30:00","slug":"non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2021\/07\/19\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/","title":{"rendered":"Non-Cystic Fibrosis Bronchiectasis Pipeline Report 2021: Analysis into Emerging Therapies and Key pharma players involved including Novartis, InsMed, Zambon, Chiesi Farmaceutici, and Many Others | DelveInsight"},"content":{"rendered":"<p><img decoding=\"async\" width=\"200\" height=\"200\" src=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/07\/5353-Delveinsight20Logo-1.jpg\" class=\"webfeedsFeaturedVisual wp-post-image\" alt=\"\" loading=\"lazy\" style=\"display: block; margin-bottom: 5px; clear:both;max-width: 100%;\" link_thumbnail=\"\" \/><\/p>\n<p><img decoding=\"async\" style=\"margin-left: auto; margin-right: auto; display: block;\" src=\"https:\/\/beta-kiosk.icrowdnewswire.com\/assets\/source\/users\/delveinsight\/Non-Cystic-Fibrosis-Bronchiectasis-Pipeline.jpg?1626668716830\" alt=\"Non-Cystic-Fibrosis-Bronchiectasis-Pipeline\" \/><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Non-cystic Fibrosis Bronchiectasis<\/strong><\/a><span style=\"font-weight: 400;\"> (henceforth referred to as bronchiectasis) is a progressive respiratory disease characterized by permanent retention of mucus, dilation of bronchi, and ciliary clearance impairment. Some Clinical features include chronic daily cough, shortness of breath, sputum, and recurrent respiratory infections, with increased morbidity and worsened quality of life. One of the keystones in management of bronchiectasis is the identification &amp; treatment of underlying causes.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&rsquo;s <\/span><strong>&lsquo;<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Non-cystic Fibrosis Bronchiectasis Pipeline Insights<\/strong><\/a><strong>&rsquo;<\/strong><span style=\"font-weight: 400;\"> report offers exhaustive coverage of the emerging therapies in different stages of development from preclinical till late-stage, along with dormant, inactive, and abandoned therapeutic agents.&nbsp;<\/span><\/p>\n<p><strong>Some of the important takeaways from the <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Non-cystic Fibrosis Bronchiectasis<\/strong> <strong>Pipeline report<\/strong><\/a><strong>:<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">NCFB Pipeline report offers an extensive analysis of 5+ key players and 5+ key therapies.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Non-cystic Fibrosis Bronchiectasis pipeline candidates are under evaluation in different stages of the clinical phase, such as CHF 6333, Brensocatib, and others expected to get launched in the foreseeable future.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Some of the key companies expanding the Non-cystic Fibrosis Bronchiectasis Pipeline are Chiesi Farmaceutici, AstraZeneca, and Insmed.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">In September 2020, US biotech Insmed trumpeted updated phase 2 data from its brensocatib at this week&rsquo;s virtual European Respiratory Society conference. It showed the drug prolonged time to exacerbations caused by the rare lung disease known as non-cystic fibrosis bronchiectasis (NCFBE).<\/span><\/li>\n<\/ul>\n<p><strong>Request for Sample Page: <\/strong><a href=\"https:\/\/www.delveinsight.com\/sample-request\/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>https:\/\/www.delveinsight.com\/sample-request\/non-cystic-fibrosis-bronchiectasis-ncfb-market<\/strong><\/a><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>NCFB Symptoms<\/strong><\/a><strong>:<\/strong><\/p>\n<p><span style=\"font-weight: 400;\">The symptoms &amp; clinical course of non-cystic fibrosis bronchiectasis are variable. Some of the patients have no symptoms at all or symptoms only during exacerbations, whereas others have them daily.<\/span><\/p>\n<p><strong>Non-cystic Fibrosis Bronchiectasis Causes<\/strong><\/p>\n<p><span style=\"font-weight: 400;\">The most common cause of NCFB in the literature is post-infectious. This is not a well-defined entity, but the usual context appears to be one acute infectious episode that is thought to result in bronchiectasis. A possible mechanism for post-infectious NCFB is a significant infection in early childhood which causes structural damage to the developing lung, allowing perpetual bacterial infection. Over time, the persistent infection may then result in bronchiectasis.<\/span><\/p>\n<p><strong>Request for Sample Page: <\/strong><a href=\"https:\/\/www.delveinsight.com\/sample-request\/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>https:\/\/www.delveinsight.com\/sample-request\/non-cystic-fibrosis-bronchiectasis-ncfb-market<\/strong><\/a><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Non-cystic Fibrosis Bronchiectasis Companies<\/strong><\/a><strong> are:<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Santhera Pharmaceuticals<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Novartis<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">InsMed<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Zambon<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Chiesi Farmaceutici<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">And Many Others<\/span><\/li>\n<\/ul>\n<p><strong>DelveInsight&rsquo;s <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>NCFB Report<\/strong><\/a><strong> covers around 5+ products under different phases of clinical development like:<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Late-stage products (Phase III)<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Discontinued &amp; Inactive candidates<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Mid-stage products (Phase II)<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Route of Administration<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Early-stage product along with the details of Pre-clinical and Discovery stage candidates<\/span><\/li>\n<\/ul>\n<p><strong>Request for Sample Page: <\/strong><a href=\"https:\/\/www.delveinsight.com\/sample-request\/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>https:\/\/www.delveinsight.com\/sample-request\/non-cystic-fibrosis-bronchiectasis-ncfb-market<\/strong><\/a><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Non-cystic Fibrosis Bronchiectasis Therapies<\/strong><\/a><strong> are:<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Lonodelestat<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Tobramycin dry-powder inhalation<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">INS-1007<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Colistimethate sodium<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">CHF 6333<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">And Many Others<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">For Deep insights into merging therapies &amp; assessment, visit <\/span><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>NCFB Pipeline: Emerging Novel Therapies&nbsp;<\/strong><\/a><\/p>\n<p><strong>Scope of the Non-Cystic Fibrosis Bronchiectasis Pipeline Report<\/strong><\/p>\n<p><strong>Coverage<\/strong><span style=\"font-weight: 400;\">: Global<\/span><\/p>\n<p><span style=\"font-weight: 400;\">&nbsp;<\/span><strong>Key Players<\/strong><span style=\"font-weight: 400;\">: Santhera Pharmaceuticals, Novartis, InsMed, Zambon, Chiesi Farmaceutici, among others.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">&nbsp;<\/span><strong>Key Non-Cystic Fibrosis Bronchiectasis Pipeline Therapies<\/strong><span style=\"font-weight: 400;\">: Lonodelestat, Tobramycin dry-powder inhalation, INS-1007, Colistimethate sodium, CHF 6333, and others.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">&nbsp;Get in touch with our Business Executives for <\/span><a href=\"https:\/\/www.delveinsight.com\/consulting?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Healthcare Consulting Solutions<\/strong><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><strong>Related Reports:<\/strong><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/cystic-fibrosis-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Cystic Fibrosis Market<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&#8217;s &#8220;Cystic Fibrosis Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Cystic Fibrosis, historical and forecasted epidemiology as well as the Cystic Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/bronchiectasis-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Bronchiectasis Market<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&#8217;s &#8220;Bronchiectasis Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Bronchiectasis, historical and forecasted epidemiology as well as the Bronchiectasis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/asthma-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Asthma Market<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&#8217;s &#8220;Asthma Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Asthma, historical and forecasted epidemiology as well as the Asthma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/bronchopulmonary-dysplasia-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Bronchopulmonary Dysplasia Market<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&#8217;s &#8220;Bronchopulmonary Dysplasia Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Bronchopulmonary Dysplasia, historical and forecasted epidemiology as well as the Bronchopulmonary Dysplasia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-bronchitis-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Chronic Bronchitis Market<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&#8217;s &#8220;Chronic Bronchitis Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Chronic Bronchitis, historical and forecasted epidemiology as well as the Chronic Bronchitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n<p><strong>Latest Blogs:<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/blog\/cardiac-monitoring-devices-market\/?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>With advancements in Innovative Technology, Cardiac Monitoring Devices Market is Booming Significantly<\/strong><\/a><a href=\"https:\/\/www.delveinsight.com\/blog\/jak-inhibitors-market\/?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>JAK Inhibitors Market<\/strong><\/a><\/li>\n<li style=\"font-weight: 400;\"><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/covid-19-vaccine-landscape\/?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Charting out the COVID-19 Vaccine Landscape<\/a><\/strong><\/li>\n<li style=\"font-weight: 400;\"><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/vagus-nerve-stimulator-market\/?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Vagus Nerve Stimulators Market Outlook<\/a><\/strong><\/li>\n<\/ul>\n<p><span style=\"text-decoration: underline;\"><strong>Other Links:<\/strong><\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/acquired-immunodeficiency-syndrome-aids-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Acquired Immunodeficiency Syndrome (AIDS) Market<\/strong><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/bladder-pain-syndrome-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Bladder pain syndrome Market<\/strong><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/cardiac-arrythmia-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Cardiac Arrhythmia Market<\/strong><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/cardiorenal-syndrome-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Cardiorenal Syndrome Market<\/strong><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/carpal-tunnel-syndrome-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Carpal Tunnel Syndrome Market<\/strong><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/central-retinal-venous-occulsion-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Central Retinal Venous Occlusion Market<\/strong><\/a><\/li>\n<\/ul>\n<p><strong>About <\/strong><a href=\"https:\/\/www.delveinsight.com\/?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>DelveInsight<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform <\/span><a href=\"https:\/\/www.pharmdelve.com\/?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>PharmDelve<\/strong><\/a><strong>.&nbsp;<\/strong><\/p>\n<p class=\"tags\">Tags: <a href=\"https:\/\/icrowdnewswire.com\/tag\/non-cystic-fibrosis-bronchiectasis-therapies\/\" rel=\"tag\">Non-Cystic Fibrosis Bronchiectasis Therapies<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/non-cystic-fibrosis-bronchiectasis-market\/\" rel=\"tag\">Non-Cystic Fibrosis Bronchiectasis Market<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/ncfb-symptoms\/\" rel=\"tag\">NCFB Symptoms<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/non-cystic-fibrosis-bronchiectasis-pipeline\/\" rel=\"tag\">Non-Cystic Fibrosis Bronchiectasis Pipeline<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/ncfb-market\/\" rel=\"tag\">NCFB Market<\/a> <\/p>\n<div><strong>See Campaign: <\/strong><a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.delveinsight.com\/<\/a><br \/><b>Contact Information:<\/b><br \/>Ankit Nigam info@delveinsight.com +19193216187<\/p>\n<p><b>Tags:<\/b><br \/><a href=\"\"><\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/reportedtimes\/\" rel=\"category tag\">Reportedtimes<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/menafn\/\" rel=\"category tag\">Menafn<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/pr-wirein\/\" rel=\"category tag\">PR-Wirein<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/ips\/\" rel=\"category tag\">IPS<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/extended-distribution\/\" rel=\"category tag\">Extended Distribution<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/icn-internal-distribution\/\" rel=\"category tag\">iCN Internal Distribution<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/research-newswire\/\" rel=\"category tag\">Research Newswire<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/language\/english\/\" rel=\"category tag\">English<\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"\" alt=\"image\" width=\"400\" height=\"300\" class=\"cwdfimg\" \/><\/div>\n<div>\n<h3>Contact Information:<\/h3>\n<p>Ankit Nigam<br \/> info@delveinsight.com<br \/> +19193216187<\/p>\n<\/p>\n<\/div>\n<p>The post <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/\">Non-Cystic Fibrosis Bronchiectasis Pipeline Report 2021: Analysis into Emerging Therapies and Key pharma players involved including Novartis, InsMed, Zambon, Chiesi Farmaceutici, and Many Others | DelveInsight<\/a> appeared first on <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\">Financial Market Brief<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Non-cystic Fibrosis Bronchiectasis (henceforth referred to as bronchiectasis) is a progressive respiratory disease characterized by permanent retention of mucus, dilation of bronchi, and ciliary clearance impairment. Some Clinical features include chronic daily cough, shortness of breath, sputum, and recurrent respiratory infections, with increased morbidity and worsened quality of life. One of the keystones in management [&hellip;]<\/p>\n<p>The post <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/\">Non-Cystic Fibrosis Bronchiectasis Pipeline Report 2021: Analysis into Emerging Therapies and Key pharma players involved including Novartis, InsMed, Zambon, Chiesi Farmaceutici, and Many Others | DelveInsight<\/a> appeared first on <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/\">Financial Market Brief<\/a>.<\/p>\n<p> <a href=\"https:\/\/ipsnews.net\/business\/2021\/07\/19\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/\" class=\"more-link\">Continue Reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":291,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-122277","post","type-post","status-publish","format-standard","hentry","category-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Non-Cystic Fibrosis Bronchiectasis Pipeline Report 2021: Analysis into Emerging Therapies and Key pharma players involved including Novartis, InsMed, Zambon, Chiesi Farmaceutici, and Many Others | DelveInsight - Business<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/ipsnews.net\/business\/2021\/07\/19\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Non-Cystic Fibrosis Bronchiectasis Pipeline Report 2021: Analysis into Emerging Therapies and Key pharma players involved including Novartis, InsMed, Zambon, Chiesi Farmaceutici, and Many Others | DelveInsight - Business\" \/>\n<meta property=\"og:description\" content=\"Non-cystic Fibrosis Bronchiectasis (henceforth referred to as bronchiectasis) is a progressive respiratory disease characterized by permanent retention of mucus, dilation of bronchi, and ciliary clearance impairment. Some Clinical features include chronic daily cough, shortness of breath, sputum, and recurrent respiratory infections, with increased morbidity and worsened quality of life. One of the keystones in management [&hellip;] The post Non-Cystic Fibrosis Bronchiectasis Pipeline Report 2021: Analysis into Emerging Therapies and Key pharma players involved including Novartis, InsMed, Zambon, Chiesi Farmaceutici, and Many Others | DelveInsight appeared first on Financial Market Brief. Continue Reading &rarr;\" \/>\n<meta property=\"og:url\" content=\"http:\/\/ipsnews.net\/business\/2021\/07\/19\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/\" \/>\n<meta property=\"og:site_name\" content=\"Business\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-19T20:30:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/07\/5353-Delveinsight20Logo-1.jpg\" \/>\n<meta name=\"author\" content=\"iCrowdNewswire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"iCrowdNewswire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/07\/19\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/\",\"url\":\"http:\/\/ipsnews.net\/business\/2021\/07\/19\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/\",\"name\":\"Non-Cystic Fibrosis Bronchiectasis Pipeline Report 2021: Analysis into Emerging Therapies and Key pharma players involved including Novartis, InsMed, Zambon, Chiesi Farmaceutici, and Many Others | DelveInsight - Business\",\"isPartOf\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#website\"},\"primaryImageOfPage\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/07\/19\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/#primaryimage\"},\"image\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/07\/19\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/07\/5353-Delveinsight20Logo-1.jpg\",\"datePublished\":\"2021-07-19T20:30:00+00:00\",\"author\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\"},\"breadcrumb\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/07\/19\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/ipsnews.net\/business\/2021\/07\/19\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/07\/19\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/#primaryimage\",\"url\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/07\/5353-Delveinsight20Logo-1.jpg\",\"contentUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/07\/5353-Delveinsight20Logo-1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/07\/19\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ipsnews.net\/business\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Non-Cystic Fibrosis Bronchiectasis Pipeline Report 2021: Analysis into Emerging Therapies and Key pharma players involved including Novartis, InsMed, Zambon, Chiesi Farmaceutici, and Many Others | DelveInsight\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ipsnews.net\/business\/#website\",\"url\":\"https:\/\/ipsnews.net\/business\/\",\"name\":\"Business\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ipsnews.net\/business\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\",\"name\":\"iCrowdNewswire\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"caption\":\"iCrowdNewswire\"},\"sameAs\":[\"https:\/\/heymuse.com\/ips\"],\"url\":\"https:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Non-Cystic Fibrosis Bronchiectasis Pipeline Report 2021: Analysis into Emerging Therapies and Key pharma players involved including Novartis, InsMed, Zambon, Chiesi Farmaceutici, and Many Others | DelveInsight - Business","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/ipsnews.net\/business\/2021\/07\/19\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/","og_locale":"en_US","og_type":"article","og_title":"Non-Cystic Fibrosis Bronchiectasis Pipeline Report 2021: Analysis into Emerging Therapies and Key pharma players involved including Novartis, InsMed, Zambon, Chiesi Farmaceutici, and Many Others | DelveInsight - Business","og_description":"Non-cystic Fibrosis Bronchiectasis (henceforth referred to as bronchiectasis) is a progressive respiratory disease characterized by permanent retention of mucus, dilation of bronchi, and ciliary clearance impairment. Some Clinical features include chronic daily cough, shortness of breath, sputum, and recurrent respiratory infections, with increased morbidity and worsened quality of life. One of the keystones in management [&hellip;] The post Non-Cystic Fibrosis Bronchiectasis Pipeline Report 2021: Analysis into Emerging Therapies and Key pharma players involved including Novartis, InsMed, Zambon, Chiesi Farmaceutici, and Many Others | DelveInsight appeared first on Financial Market Brief. Continue Reading &rarr;","og_url":"http:\/\/ipsnews.net\/business\/2021\/07\/19\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/","og_site_name":"Business","article_published_time":"2021-07-19T20:30:00+00:00","og_image":[{"url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/07\/5353-Delveinsight20Logo-1.jpg","type":"","width":"","height":""}],"author":"iCrowdNewswire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"iCrowdNewswire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/ipsnews.net\/business\/2021\/07\/19\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/","url":"http:\/\/ipsnews.net\/business\/2021\/07\/19\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/","name":"Non-Cystic Fibrosis Bronchiectasis Pipeline Report 2021: Analysis into Emerging Therapies and Key pharma players involved including Novartis, InsMed, Zambon, Chiesi Farmaceutici, and Many Others | DelveInsight - Business","isPartOf":{"@id":"https:\/\/ipsnews.net\/business\/#website"},"primaryImageOfPage":{"@id":"http:\/\/ipsnews.net\/business\/2021\/07\/19\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/#primaryimage"},"image":{"@id":"http:\/\/ipsnews.net\/business\/2021\/07\/19\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/#primaryimage"},"thumbnailUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/07\/5353-Delveinsight20Logo-1.jpg","datePublished":"2021-07-19T20:30:00+00:00","author":{"@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee"},"breadcrumb":{"@id":"http:\/\/ipsnews.net\/business\/2021\/07\/19\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/ipsnews.net\/business\/2021\/07\/19\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/ipsnews.net\/business\/2021\/07\/19\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/#primaryimage","url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/07\/5353-Delveinsight20Logo-1.jpg","contentUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/07\/5353-Delveinsight20Logo-1.jpg"},{"@type":"BreadcrumbList","@id":"http:\/\/ipsnews.net\/business\/2021\/07\/19\/non-cystic-fibrosis-bronchiectasis-pipeline-report-2021-analysis-into-emerging-therapies-and-key-pharma-players-involved-including-novartis-insmed-zambon-chiesi-farmaceutici-and-many-others-del\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipsnews.net\/business\/"},{"@type":"ListItem","position":2,"name":"Non-Cystic Fibrosis Bronchiectasis Pipeline Report 2021: Analysis into Emerging Therapies and Key pharma players involved including Novartis, InsMed, Zambon, Chiesi Farmaceutici, and Many Others | DelveInsight"}]},{"@type":"WebSite","@id":"https:\/\/ipsnews.net\/business\/#website","url":"https:\/\/ipsnews.net\/business\/","name":"Business","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipsnews.net\/business\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee","name":"iCrowdNewswire","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","caption":"iCrowdNewswire"},"sameAs":["https:\/\/heymuse.com\/ips"],"url":"https:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/122277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/users\/291"}],"replies":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/comments?post=122277"}],"version-history":[{"count":1,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/122277\/revisions"}],"predecessor-version":[{"id":122278,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/122277\/revisions\/122278"}],"wp:attachment":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/media?parent=122277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/categories?post=122277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/tags?post=122277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}